The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nxstage Medical's revenues will improve 8.0% and EPS will remain in the red.
The average estimate for revenue is $58.1 million. On the bottom line, the average EPS estimate is -$0.09.
Last quarter, Nxstage Medical booked revenue of $57.0 million. GAAP reported sales were 13% higher than the prior-year quarter's $50.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.09. GAAP EPS were -$0.09 for Q1 against -$0.11 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 37.4%, 170 basis points better than the prior-year quarter. Operating margin was -6.4%, 280 basis points better than the prior-year quarter. Net margin was -9.0%, 290 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.28.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 136 members out of 169 rating the stock outperform, and 33 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Nxstage Medical a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $26.00.
- Add Nxstage Medical to My Watchlist.